Literature DB >> 28302627

Inhibition of Smooth Muscle β-Catenin Hinders Neointima Formation After Vascular Injury.

Dario F Riascos-Bernal1, Prameladevi Chinnasamy1, Jordana N Gross1, Vanessa Almonte1, Lander Egaña-Gorroño1, Dippal Parikh1, Smitha Jayakumar1, Liang Guo1, Nicholas E S Sibinga2.   

Abstract

OBJECTIVE: Smooth muscle cells (SMCs) contribute to neointima formation after vascular injury. Although β-catenin expression is induced after injury, whether its function is essential in SMCs for neointimal growth is unknown. Moreover, although inhibitors of β-catenin have been developed, their effects on SMC growth have not been tested. We assessed the requirement for SMC β-catenin in short-term vascular homeostasis and in response to arterial injury and investigated the effects of β-catenin inhibitors on vascular SMC growth. APPROACH AND
RESULTS: We used an inducible, conditional genetic deletion of β-catenin in SMCs of adult mice. Uninjured arteries from adult mice lacking SMC β-catenin were indistinguishable from controls in terms of structure and SMC marker gene expression. After carotid artery ligation, however, vessels from mice lacking SMC β-catenin developed smaller neointimas, with lower neointimal cell proliferation and increased apoptosis. SMCs lacking β-catenin showed decreased mRNA expression of Mmp2, Mmp9, Sphk1, and S1pr1 (genes that promote neointima formation), higher levels of Jag1 and Gja1 (genes that inhibit neointima formation), decreased Mmp2 protein expression and secretion, and reduced cell invasion in vitro. Moreover, β-catenin inhibitors PKF118-310 and ICG-001 limited growth of mouse and human vascular SMCs in a dose-dependent manner.
CONCLUSIONS: SMC β-catenin is dispensable for maintenance of the structure and state of differentiation of uninjured adult arteries, but is required for neointima formation after vascular injury. Pharmacological β-catenin inhibitors hinder growth of human vascular SMCs. Thus, inhibiting β-catenin has potential as a therapy to limit SMC accumulation and vascular obstruction.
© 2017 American Heart Association, Inc.

Entities:  

Keywords:  beta-catenin; beta-catenin inhibitors; myocytes, smooth muscle; neointima; vascular injury

Mesh:

Substances:

Year:  2017        PMID: 28302627      PMCID: PMC5408313          DOI: 10.1161/ATVBAHA.116.308643

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  51 in total

1.  Matrix metalloproteinase-9 overexpression enhances vascular smooth muscle cell migration and alters remodeling in the injured rat carotid artery.

Authors:  D P Mason; R D Kenagy; D Hasenstab; D F Bowen-Pope; R A Seifert; S Coats; S M Hawkins; A W Clowes
Journal:  Circ Res       Date:  1999 Dec 3-17       Impact factor: 17.367

2.  Matrix metalloproteinase 2 and tissue inhibitors of metalloproteinases regulate human aortic smooth muscle cell migration during in vitro aging.

Authors:  Davide Vigetti; Paola Moretto; Manuela Viola; Anna Genasetti; Manuela Rizzi; Evgenia Karousou; Francesco Pallotti; Giancarlo De Luca; Alberto Passi
Journal:  FASEB J       Date:  2006-06       Impact factor: 5.191

3.  Matrix metalloproteinase (MMP)-3 activates MMP-9 mediated vascular smooth muscle cell migration and neointima formation in mice.

Authors:  Jason L Johnson; Amrita Dwivedi; Michelle Somerville; Sarah J George; Andrew C Newby
Journal:  Arterioscler Thromb Vasc Biol       Date:  2011-06-30       Impact factor: 8.311

4.  Small molecule antagonists of Tcf4/beta-catenin complex inhibit the growth of HCC cells in vitro and in vivo.

Authors:  Wei Wei; Mei-Sze Chua; Susan Grepper; Samuel So
Journal:  Int J Cancer       Date:  2010-05-15       Impact factor: 7.396

5.  Smooth muscle cell plasticity: fact or fiction?

Authors:  Anh T Nguyen; Delphine Gomez; Robert D Bell; Julie H Campbell; Alexander W Clowes; Giulio Gabbiani; Cecilia M Giachelli; Michael S Parmacek; Elaine W Raines; Nancy J Rusch; Mei Y Speer; Michael Sturek; Johan Thyberg; Dwight A Towler; Mary C Weiser-Evans; Chen Yan; Joseph M Miano; Gary K Owens
Journal:  Circ Res       Date:  2012-10-23       Impact factor: 17.367

6.  Wnt2 and WISP-1/CCN4 Induce Intimal Thickening via Promotion of Smooth Muscle Cell Migration.

Authors:  Helen Williams; Carina A E Mill; Bethan A Monk; Sarah Hulin-Curtis; Jason L Johnson; Sarah J George
Journal:  Arterioscler Thromb Vasc Biol       Date:  2016-05-19       Impact factor: 8.311

7.  A small molecule inhibitor of beta-catenin/CREB-binding protein transcription [corrected].

Authors:  Katayoon H Emami; Cu Nguyen; Hong Ma; Dae Hoon Kim; Kwang Won Jeong; Masakatsu Eguchi; Randall T Moon; Jia-Ling Teo; Se Woong Oh; Hak Yeop Kim; Sung Hwan Moon; Jong Ryul Ha; Michael Kahn
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-16       Impact factor: 11.205

8.  Absence of p53 leads to accelerated neointimal hyperplasia after vascular injury.

Authors:  Masataka Sata; Kimie Tanaka; Nobukazu Ishizaka; Yasunobu Hirata; Ryozo Nagai
Journal:  Arterioscler Thromb Vasc Biol       Date:  2003-07-31       Impact factor: 8.311

9.  Kindlin-2 siRNA inhibits vascular smooth muscle cell proliferation, migration and intimal hyperplasia via Wnt signaling.

Authors:  Xiaolin Wu; Wenwei Liu; Hong Jiang; Jing Chen; Jichun Wang; Rui Zhu; Bin Li
Journal:  Int J Mol Med       Date:  2015-12-10       Impact factor: 4.101

10.  Inactivation of the beta-catenin gene by Wnt1-Cre-mediated deletion results in dramatic brain malformation and failure of craniofacial development.

Authors:  V Brault; R Moore; S Kutsch; M Ishibashi; D H Rowitch; A P McMahon; L Sommer; O Boussadia; R Kemler
Journal:  Development       Date:  2001-04       Impact factor: 6.868

View more
  9 in total

Review 1.  Smooth Muscle Cells in Vascular Remodeling.

Authors:  Ning Shi; Xiaohan Mei; Shi-You Chen
Journal:  Arterioscler Thromb Vasc Biol       Date:  2019-11-26       Impact factor: 8.311

Review 2.  The Atypical Cadherin FAT1 Limits Mitochondrial Respiration and Proliferation of Vascular Smooth Muscle Cells.

Authors:  Dario F Riascos-Bernal; Alishba Maira; Nicholas E S Sibinga
Journal:  Front Cardiovasc Med       Date:  2022-05-11

3.  Reporting Sex and Sex Differences in Preclinical Studies.

Authors:  Hong S Lu; Ann Marie Schmidt; Robert A Hegele; Nigel Mackman; Daniel J Rader; Christian Weber; Alan Daugherty
Journal:  Arterioscler Thromb Vasc Biol       Date:  2018-10       Impact factor: 8.311

Review 4.  Role of smooth muscle cells in coronary artery bypass grafting failure.

Authors:  Kerry Wadey; Joshua Lopes; Michelle Bendeck; Sarah George
Journal:  Cardiovasc Res       Date:  2018-03-15       Impact factor: 10.787

5.  Epac1 deficiency inhibits basic fibroblast growth factor-mediated vascular smooth muscle cell migration.

Authors:  Yuko Kato; Utako Yokoyama; Takayuki Fujita; Masanari Umemura; Tetsuo Kubota; Yoshihiro Ishikawa
Journal:  J Physiol Sci       Date:  2018-08-06       Impact factor: 2.781

6.  An Ex Vivo Vessel Injury Model to Study Remodeling.

Authors:  Mehmet H Kural; Guohao Dai; Laura E Niklason; Liqiong Gui
Journal:  Cell Transplant       Date:  2018-08-10       Impact factor: 4.064

7.  Sodium Selenite Attenuates Balloon Injury-Induced and Monocrotaline-Induced Vascular Remodeling in Rats.

Authors:  Changhong Cai; Yonghui Wu; Lebing Yang; Yijia Xiang; Ning Zhu; Huan Zhao; Wuming Hu; Lingchun Lv; Chunlai Zeng
Journal:  Front Pharmacol       Date:  2021-03-15       Impact factor: 5.810

8.  Cezanne is a critical regulator of pathological arterial remodelling by targeting β-catenin signalling.

Authors:  Weiwei An; Le A Luong; Neil P Bowden; Mei Yang; Wei Wu; Xinmiao Zhou; Chenxin Liu; Kaiyuan Niu; Jun Luo; Cheng Zhang; Xiaolei Sun; Robin Poston; Li Zhang; Paul C Evans; Qingzhong Xiao
Journal:  Cardiovasc Res       Date:  2022-01-29       Impact factor: 13.081

9.  Periostin Augments Vascular Smooth Muscle Cell Calcification via β-Catenin Signaling.

Authors:  Ioana Alesutan; Laura A Henze; Beate Boehme; Trang T D Luong; Daniel Zickler; Burkert Pieske; Kai-Uwe Eckardt; Andreas Pasch; Jakob Voelkl
Journal:  Biomolecules       Date:  2022-08-21
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.